April 8, 2021 -- Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation.
The deal includes a cash payment of approximately $714 million for Mobidiag's equity and net debt of approximately $81 million.
Mobidiag develops and markets polymerase chain reaction (PCR)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections. The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
Mobidiag generated approximately $42 million in revenue in calendar year 2020. Hologic said it intends to invest in assay development to drive growth of the Novodiag platform.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current